Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 46 to 60 of 120 results for multiple sclerosis

  1. NICE recommends that a new model for multiple sclerosis is developed, ideally based on UK patient cohorts, which uses the best available evidence (including experience to date from the risk-sharing scheme) and includes all currently available treatments.

    TA254/2 Question NICE recommends that a new model for multiple sclerosis is developed, ideally based on UK patient cohorts, which uses...

  2. Multiple long-term conditions: medication review (IND207)

    This indicator covers the percentage of patients with moderate or severe frailty and/or multimorbidity who have received a medication review in the last 12 months which is structured, has considered the use of a recognised tool and taken place as a shared discussion. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM186

  3. Past appeals and decisions

    disease - riluzole 4 January 2001 TA129 Multiple myeloma - Bortezomib 8 February 2007 TA228 Multiple myeloma (first line) -...

  4. NICE visualisation of treatment options incorporating technology appraisals: interim process guide (PMG38)

    NICE visualisation of treatment options incorporating technology appraisals: interim process guide

  5. Dimethyl fumarate for treating relapsing-remitting multiple sclerosis in people aged 13 to 17 TS ID 11778

      Status ...

  6. Stereotactic radiosurgery for trigeminal neuralgia (IPG715)

    Evidence-based recommendations on stereotactic radiosurgery for trigeminal neuralgia in adults. This involves focusing radiation on the trigeminal nerve to damage it, thereby relieving pain.

  7. Multiple sclerosis - sativex [ID387]

    Discontinued [GID-TAG368]

  8. QTUG for assessing falls risk and frailty (MIB73)

    NICE has developed a medtech innovation briefing (MIB) on the Quantitative Timed Up and Go (QTUG)

  9. Biotin for treating primary and secondary progressive multiple sclerosis [ID919]

    Discontinued [GID-TA10099]

  10. Laquinimod for treating relapsing-remitting multiple sclerosis [ID560]

    Discontinued [GID-TAG337]

  11. Multiple sclerosis (primary-progressive) - fingolimod [ID62]

    Discontinued [GID-TAG221]

  12. What is the clinical and cost effectiveness of cannabis-based medicinal products other than THC: CBD spray for children, young people and adults with spasticity? In particular, what is the impact of spasticity on improvements in quality of life?

    (licensed product in UK: Sativex) for treating spasticity in people with multiple sclerosis. There were reductions in some measures of...

  13. Autologous haematopoietic stem cell transplantation for treating multiple sclerosis [ID1111]

    Discontinued [GID-TA10306]

  14. Percutaneous posterior tibial nerve stimulation for overactive bladder syndrome (IPG362)

    Evidence-based recommendations on percutaneous posterior tibial nerve stimulation for overactive bladder syndrome. This involves inserting a fine needle into a nerve just above the ankle and passing a mild electric current to the nerves that control bladder function.

  15. Injectable bulking agents for faecal incontinence (IPG210)

    Evidence-based recommendations on injectable bulking agents for faecal incontinence. This involves injecting a material into the muscles around the anus to bulk the sides of the sphincter.